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TO THE EDITOR
We really appreciated the results of the ob-
servational study conducted by Terlecki et 
al. [1], who demonstrated that, in a total of 
1729 patients admitted to hospital due to 
coronavirus disease 2019 (COVID-19), history 
of diabetes mellitus significantly increased 
the odds of in-hospital death by 53%, while 
those patients with concomitant heart failure 
(HF) experienced a two-fold increase in the 
corresponding odds. Researchers have also 
shown in their cohort that prior treatment with 
renin-angiotensin-aldosterone system blockers, 
statins, antiplatelet drugs, or beta-blockers was 
associated with a significant decrease in the 
odds of in-hospital death, confirming a protec-
tive role of these drug classes against the most 
surrogate COVID-19 outcome [1]. 
Recently, there has been a vivid and ongoing 
discussion concerning the place of sodium- 
-glucose co-transporter-2 (SGLT-2) inhibitors in 
the therapeutic management of patients with 
COVID-19 [2]. This drug class has an established 
role in the treatment of type 2 diabetes mellitus, 
while it has gained significant ground in the 
treatment armamentarium against HF, espe-
cially in patients with HF with reduced ejection 
fraction (HFrEF), even without concomitant type 
2 diabetes mellitus [3]. 
According to a recently published nation-
wide cohort study from the National Diabetes 
Audit in England, prescription of SGLT-2 inhib-
itors is associated with a significant decrease in 
the risk for COVID-19 related death by 18% [4]. 
However, relevant data remain scarce and con-
flicting, as far as pathophysiologic background 
is concerned, and thus, further research on this 
field is required [5]. 
Therefore, it would be very interesting and 
would increase a value of the initial report, if 
Terlecki et al. [1] could provide data concerning 
the usage rates of SGLT-2 inhibitors in their co-
hort and the association with crude outcomes, 
such as mechanical ventilation and in-hospital 
death, since this “miraculous” drug class has 
attracted scientific interest, with an established 
role in the secondary prevention of cardiovas-
cular disease. Data from such real-world studies 
may influence decision-making and improve 
therapeutic strategy if we confront another 
COVID-19 pandemic wave in the near future. 
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